Tonix Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TNXP)

$3.40 +0.02 (+0.59 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$3.40
Today's Range$3.30 - $3.43
52-Week Range$2.85 - $9.40
Volume18,096 shs
Average Volume55,496 shs
Market Capitalization$26.52 million
P/E Ratio-0.71
Dividend YieldN/A
Beta3.01

About Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals logoTonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The company’s product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TNXP
CUSIPN/A
Phone212-980-9155

Debt

Debt-to-Equity RatioN/A
Current Ratio16.50%
Quick Ratio16.50%

Price-To-Earnings

Trailing P/E Ratio-0.712788259958071
Forward P/E Ratio-1.05
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.47 per share
Price / Book0.53

Profitability

Trailing EPS($4.77)
Net Income$-38,840,000.00
Net MarginsN/A
Return on Equity-78.25%
Return on Assets-73.14%

Miscellaneous

Employees18
Outstanding Shares7,800,000

Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.65) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.78) by $0.13. View Tonix Pharmaceuticals' Earnings History.

When will Tonix Pharmaceuticals make its next earnings announcement?

Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April, 16th 2018. View Earnings Estimates for Tonix Pharmaceuticals.

Where is Tonix Pharmaceuticals' stock going? Where will Tonix Pharmaceuticals' stock price be in 2018?

4 brokerages have issued twelve-month price targets for Tonix Pharmaceuticals' stock. Their forecasts range from $6.00 to $10.00. On average, they expect Tonix Pharmaceuticals' share price to reach $8.33 in the next twelve months. View Analyst Ratings for Tonix Pharmaceuticals.

Who are some of Tonix Pharmaceuticals' key competitors?

Who owns Tonix Pharmaceuticals stock?

Tonix Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include B. Riley Financial Inc. (1.15%) and Renaissance Technologies LLC (0.96%). Company insiders that own Tonix Pharmaceuticals stock include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.

Who sold Tonix Pharmaceuticals stock? Who is selling Tonix Pharmaceuticals stock?

Tonix Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including B. Riley Financial Inc.. View Insider Buying and Selling for Tonix Pharmaceuticals.

Who bought Tonix Pharmaceuticals stock? Who is buying Tonix Pharmaceuticals stock?

Tonix Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals.

How do I buy Tonix Pharmaceuticals stock?

Shares of Tonix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tonix Pharmaceuticals' stock price today?

One share of Tonix Pharmaceuticals stock can currently be purchased for approximately $3.40.

How big of a company is Tonix Pharmaceuticals?

Tonix Pharmaceuticals has a market capitalization of $26.52 million. The company earns $-38,840,000.00 in net income (profit) each year or ($4.77) on an earnings per share basis. Tonix Pharmaceuticals employs 18 workers across the globe.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVE. - SUITE 306, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]


MarketBeat Community Rating for Tonix Pharmaceuticals (TNXP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tonix Pharmaceuticals (NASDAQ:TNXP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.802.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.33$8.33$8.33$8.33
Price Target Upside: 117.01% upside117.01% upside159.61% upside159.61% upside

Tonix Pharmaceuticals (NASDAQ:TNXP) Consensus Price Target History

Price Target History for Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals (NASDAQ:TNXP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/1/2017AegisReiterated RatingBuyMediumView Rating Details
8/23/2017Dawson JamesReiterated RatingBuy$9.00MediumView Rating Details
8/22/2017Drexel HamiltonInitiated CoverageBuyHighView Rating Details
8/18/2017Roth CapitalUpgradeNeutral -> Buy$6.00HighView Rating Details
12/20/2016OppenheimerReiterated RatingHoldN/AView Rating Details
9/7/2016Cantor FitzgeraldDowngradeBuy -> HoldN/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Tonix Pharmaceuticals (NASDAQ:TNXP) Earnings History and Estimates Chart

Earnings by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals (NASDAQ TNXP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/16/2018N/AView Earnings Details
11/7/2017Q3 2017($0.68)($0.70)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.78)($0.65)ViewN/AView Earnings Details
5/15/2017Q1 2017($1.36)($1.27)ViewN/AView Earnings Details
4/17/2017Q4 2016($1.77)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.34)($0.29)ViewN/AView Earnings Details
8/5/2016Q2 2016($5.60)($5.00)ViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.74)ViewN/AView Earnings Details
3/4/2016Q4($0.66)($0.71)ViewN/AView Earnings Details
11/9/2015Q3 2015($6.00)($6.70)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.73)ViewN/AView Earnings Details
5/11/2015Q115($0.54)($0.71)ViewN/AView Earnings Details
3/3/2015Q414($0.81)($0.83)ViewN/AView Earnings Details
11/10/2014Q314($0.69)($0.71)ViewN/AView Earnings Details
8/8/2014Q214($0.53)($0.61)ViewN/AView Earnings Details
5/13/2014Q114($0.35)($0.59)ViewN/AView Earnings Details
3/31/2014($0.46)($0.74)ViewN/AView Earnings Details
11/13/2013Q3 2013($5.60)($8.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Tonix Pharmaceuticals (NASDAQ:TNXP) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.23 EPS
Next Year EPS Consensus Estimate: $-2.08 EPS

Dividends

Dividend History for Tonix Pharmaceuticals (NASDAQ:TNXP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Tonix Pharmaceuticals (NASDAQ TNXP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 16.26%
Insider Trades by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)
Insider Trades by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals (NASDAQ TNXP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/26/2017Seth LedermanCEOBuy5,300$3.61$19,133.0011,166View SEC Filing  
12/21/2017Ernest MarioDirectorSell36,967$3.51$129,754.1710,000View SEC Filing  
12/18/2017Ernest MarioDirectorSell10,000$3.57$35,700.0010,000View SEC Filing  
12/14/2017Ernest MarioDirectorSell1,967$3.58$7,041.8610,000View SEC Filing  
8/17/2017Seth LedermanCEOBuy20,000$3.00$60,000.0011,166View SEC Filing  
6/30/2017Ernest MarioDirectorSell6,105$4.28$26,129.4063,073View SEC Filing  
6/30/2017Seth LedermanCEOBuy5,000$4.33$21,650.007,912View SEC Filing  
6/26/2017Seth LedermanCEOBuy5,000$4.40$22,000.007,912View SEC Filing  
6/20/2017Seth LedermanCEOBuy20,000$4.22$84,400.007,912View SEC Filing  
11/23/2016Ernest MarioDirectorBuy120,000$0.41$49,200.00630,724View SEC Filing  
9/13/2016Ernest MarioDirectorBuy100,000$0.79$79,000.00530,724View SEC Filing  
6/22/2016Seth LedermanCEOBuy20,000$2.08$41,600.0080,815View SEC Filing  
6/21/2016Bradley SaengerCFOBuy2,000$2.00$4,000.006,039View SEC Filing  
6/21/2016Bruce DaughertyInsiderBuy100,000$2.00$200,000.0065,777View SEC Filing  
6/21/2016John B RhodesDirectorBuy25,000$2.00$50,000.00112,196View SEC Filing  
6/3/2016Gregory M SullivanInsiderBuy20,000$2.50$50,000.0043,185View SEC Filing  
5/12/2016Ernest MarioDirectorBuy31,042$2.30$71,396.60380,724View SEC Filing  
5/11/2016Ernest MarioDirectorBuy8,210$2.24$18,390.40349,682View SEC Filing  
3/23/2016Seth LedermanCEOBuy8,000$2.44$19,520.0080,815View SEC Filing  
3/16/2016Ernest MarioDirectorBuy75,000$2.29$171,750.00341,472View SEC Filing  
9/30/2015Gregory M SullivanInsiderBuy5,000$5.18$25,900.0016,925View SEC Filing  
9/28/2015Gregory M SullivanInsiderBuy4,694$5.95$27,929.3011,925View SEC Filing  
9/25/2015Seth LedermanCEOBuy6,000$6.50$39,000.0071,074View SEC Filing  
8/26/2015Ernest MarioDirectorBuy10,000$6.05$60,500.00260,472View SEC Filing  
8/25/2015Ernest MarioDirectorBuy1,468$6.40$9,395.20250,472View SEC Filing  
8/24/2015Ernest MarioDirectorBuy2,532$6.20$15,698.40249,004View SEC Filing  
8/20/2015Ernest MarioDirectorBuy6,000$6.64$39,840.00246,472View SEC Filing  
8/17/2015Ernest MarioDirectorBuy15,000$6.93$103,950.00View SEC Filing  
7/17/2015John B RhodesDirectorBuy6,000$7.50$45,000.00View SEC Filing  
7/17/2015Leland GershellCFOBuy1,000$7.50$7,500.00View SEC Filing  
6/11/2015Gregory M SullivanInsiderBuy4,500$8.38$37,710.00View SEC Filing  
3/17/2015Seth LedermanCEOBuy2,000$7.02$14,040.00View SEC Filing  
3/13/2015Seth LedermanCEOBuy2,000$7.24$14,480.00View SEC Filing  
3/11/2015Seth LedermanCEOBuy2,000$6.95$13,900.00View SEC Filing  
3/10/2015Charles E Iv MatherDirectorBuy1,000$6.80$6,800.00View SEC Filing  
3/9/2015Seth LedermanCEOBuy2,000$6.48$12,960.00View SEC Filing  
3/6/2015Ernest MarioDirectorBuy4,000$6.57$26,280.00View SEC Filing  
3/5/2015Seth LedermanCEOBuy2,000$6.27$12,540.00View SEC Filing  
2/9/2015Ernest MarioDirectorBuy30,000$5.85$175,500.00View SEC Filing  
2/9/2015Leland GershellCFOBuy5,000$5.85$29,250.00View SEC Filing  
9/27/2013Charles E Iv MatherDirectorBuy1,000$3.65$3,650.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tonix Pharmaceuticals (NASDAQ TNXP) News Headlines

Source:
DateHeadline
-$0.77 Earnings Per Share Expected for Tonix Pharmaceuticals Holding Corp. (TNXP) This Quarter-$0.77 Earnings Per Share Expected for Tonix Pharmaceuticals Holding Corp. (TNXP) This Quarter
www.americanbankingnews.com - February 21 at 7:10 PM
Tonix Pharmaceuticals (TNPX) Presents At BIO CEO & Investor Conference - SlideshowTonix Pharmaceuticals (TNPX) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:21 PM
Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO ... - GlobeNewswire (press release)Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 5:54 AM
Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York CityTonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City
finance.yahoo.com - February 8 at 5:54 AM
Tonix Pharmaceuticals to Present at Noble Capital Markets Fourteenth Annual Investor Conference in Fort Lauderdale - GlobeNewswire (press release)Tonix Pharmaceuticals to Present at Noble Capital Markets' Fourteenth Annual Investor Conference in Fort Lauderdale - GlobeNewswire (press release)
globenewswire.com - January 26 at 3:20 PM
Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort LauderdaleTonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale
finance.yahoo.com - January 25 at 6:06 AM
Tonix Pharma (TNXP) Reports Notice of Allowance for New U.S. ... - StreetInsider.comTonix Pharma (TNXP) Reports Notice of Allowance for New U.S. ... - StreetInsider.com
www.streetinsider.com - January 23 at 3:25 PM
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
finance.yahoo.com - January 23 at 9:32 AM
Blog Exposure - Tonix Declares Publication of Research about Potential Smallpox-Preventing Vaccine Candidate TNX-801Blog Exposure - Tonix Declares Publication of Research about Potential Smallpox-Preventing Vaccine Candidate TNX-801
finance.yahoo.com - January 23 at 9:32 AM
Tonix Pharmaceuticals receives notice of allowance for new U.S. patent for the active ingredient in TonmyaTonix Pharmaceuticals receives notice of allowance for new U.S. patent for the active ingredient in Tonmya
seekingalpha.com - January 23 at 8:55 AM
Tonix Pharma (TNXP) Announces Publication Reporting Synthesis ... - StreetInsider.comTonix Pharma (TNXP) Announces Publication Reporting Synthesis ... - StreetInsider.com
www.streetinsider.com - January 21 at 5:47 AM
Successful Development of TNX-801 May Lead to an Improved Smallpox-Preventing VaccineSuccessful Development of TNX-801 May Lead to an Improved Smallpox-Preventing Vaccine
www.nasdaq.com - January 19 at 3:42 PM
Tonix Pharma (TNXP) Announces Jessica Morris as COO - StreetInsider.comTonix Pharma (TNXP) Announces Jessica Morris as COO - StreetInsider.com
www.streetinsider.com - January 10 at 3:33 PM
Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating ... - GlobeNewswire (press release)Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating ... - GlobeNewswire (press release)
globenewswire.com - January 9 at 3:34 PM
Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating OfficerTonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer
finance.yahoo.com - January 9 at 11:16 AM
TNXP: Ready to File IND to Study TNX 102-SL in Agitation in Alzheimer’s DiseaseTNXP: Ready to File IND to Study TNX 102-SL in Agitation in Alzheimer’s Disease
finance.yahoo.com - January 8 at 3:38 PM
What Are Analysts Saying About Tonix Pharmaceuticals Holding Corp’s (NASDAQ:TNXP) Future?What Are Analysts Saying About Tonix Pharmaceuticals Holding Corp’s (NASDAQ:TNXP) Future?
finance.yahoo.com - January 6 at 9:33 AM
Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San FranciscoTonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco
finance.yahoo.com - January 3 at 10:57 AM
Tonix Pharmaceuticals (TNXP) Downgraded by ValuEngineTonix Pharmaceuticals (TNXP) Downgraded by ValuEngine
www.americanbankingnews.com - January 1 at 8:32 AM
Tonix Pharmaceuticals Holding Corp. (TNXP) CEO Purchases $19,133.00 in StockTonix Pharmaceuticals Holding Corp. (TNXP) CEO Purchases $19,133.00 in Stock
www.americanbankingnews.com - December 28 at 5:56 PM
Insider Selling: Tonix Pharmaceuticals Holding Corp. (TNXP) Director Sells 10,000 Shares of StockInsider Selling: Tonix Pharmaceuticals Holding Corp. (TNXP) Director Sells 10,000 Shares of Stock
www.americanbankingnews.com - December 22 at 6:13 PM
Tonix Pharmaceuticals Holding Corp. (TNXP) Director Ernest Mario Sells 36,967 SharesTonix Pharmaceuticals Holding Corp. (TNXP) Director Ernest Mario Sells 36,967 Shares
www.americanbankingnews.com - December 22 at 5:54 PM
FY2017 EPS Estimates for Tonix Pharmaceuticals Holding Corp. Lowered by Analyst (TNXP)FY2017 EPS Estimates for Tonix Pharmaceuticals Holding Corp. Lowered by Analyst (TNXP)
www.americanbankingnews.com - December 18 at 1:04 AM
 Brokerages Expect Tonix Pharmaceuticals Holding Corp. (TNXP) Will Announce Earnings of -$0.77 Per Share Brokerages Expect Tonix Pharmaceuticals Holding Corp. (TNXP) Will Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - December 16 at 9:30 AM
TNXP: The Origin of the Smallpox Vaccine and the Implications for TNX-801TNXP: The Origin of the Smallpox Vaccine and the Implications for TNX-801
finance.yahoo.com - December 13 at 3:33 PM
Tonix Pharma (TNXP) Reports Completion of Positive Pre-IND ... - StreetInsider.comTonix Pharma (TNXP) Reports Completion of Positive Pre-IND ... - StreetInsider.com
www.streetinsider.com - December 12 at 11:22 AM
Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s DiseaseTonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease
finance.yahoo.com - December 12 at 11:22 AM
Head-To-Head Survey: Tonix Pharmaceuticals (TNXP) & Innovus Pharmaceuticals (INNV)Head-To-Head Survey: Tonix Pharmaceuticals (TNXP) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - December 10 at 9:08 PM
Head to Head Review: Echo Therapeutics (ECTE) & Tonix Pharmaceuticals (TNXP)Head to Head Review: Echo Therapeutics (ECTE) & Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - December 9 at 11:42 PM
Tonix Pharmaceuticals (TNXP) Buy Rating Reaffirmed at AegisTonix Pharmaceuticals' (TNXP) Buy Rating Reaffirmed at Aegis
www.americanbankingnews.com - December 7 at 7:00 PM
Tonix Pharmaceuticals (TNXP) Rating Lowered to Strong Sell at ValuEngineTonix Pharmaceuticals (TNXP) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - December 2 at 10:26 AM
Reviewing Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)Reviewing Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - December 2 at 1:30 AM
Tonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Rating of "Buy" from AnalystsTonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 1 at 3:54 PM
Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor ... - GlobeNewswire (press release)Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor ... - GlobeNewswire (press release)
globenewswire.com - November 30 at 3:32 PM
Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor ConferenceTonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference
feeds.benzinga.com - November 30 at 7:52 AM
Tonix Pharmaceuticals (TNXP) versus Innovus Pharmaceuticals (INNV) Head-To-Head ReviewTonix Pharmaceuticals (TNXP) versus Innovus Pharmaceuticals (INNV) Head-To-Head Review
www.americanbankingnews.com - November 28 at 3:34 PM
 Analysts Expect Tonix Pharmaceuticals Holding Corp. (TNXP) Will Announce Earnings of -$0.72 Per Share Analysts Expect Tonix Pharmaceuticals Holding Corp. (TNXP) Will Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - November 28 at 3:27 AM
Echo Therapeutics (ECTE) vs. Tonix Pharmaceuticals (TNXP) Head-To-Head ContrastEcho Therapeutics (ECTE) vs. Tonix Pharmaceuticals (TNXP) Head-To-Head Contrast
www.americanbankingnews.com - November 27 at 10:26 AM
Contrasting Echo Therapeutics (ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)Contrasting Echo Therapeutics (ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - November 18 at 5:42 AM
Head to Head Survey: Echo Therapeutics (ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)Head to Head Survey: Echo Therapeutics (ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - November 15 at 5:27 PM
Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs UpdateTonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update
finance.yahoo.com - November 7 at 12:15 PM
Tonix reports 3Q lossTonix reports 3Q loss
finance.yahoo.com - November 7 at 12:15 PM
Tonix Pharmaceuticals Holding Corp. (TNXP) Receives Consensus Recommendation of "Buy" from AnalystsTonix Pharmaceuticals Holding Corp. (TNXP) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 6 at 10:35 AM
Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering ConferenceTonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference
finance.yahoo.com - November 1 at 9:44 AM
Tonix Pharmaceuticals Holding Corp. (TNXP) to Release Quarterly Earnings on WednesdayTonix Pharmaceuticals Holding Corp. (TNXP) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
Tonix Pharmaceuticals (TNXP) Presents At 3rd Annual Dawson James Small Cap Growth Conference 2017 - SlideshowTonix Pharmaceuticals (TNXP) Presents At 3rd Annual Dawson James Small Cap Growth Conference 2017 - Slideshow
seekingalpha.com - October 21 at 9:23 AM
-$0.68 Earnings Per Share Expected for Tonix Pharmaceuticals Holding Corp. (TNXP) This Quarter-$0.68 Earnings Per Share Expected for Tonix Pharmaceuticals Holding Corp. (TNXP) This Quarter
www.americanbankingnews.com - October 20 at 6:24 PM
BRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on TonmyaBRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya
www.reuters.com - October 19 at 9:55 AM
Tonix Pharma (TNXP) Says in General Its Proposed CMC Data Package to Support Tonmyas NDA and Commercial ... - StreetInsider.comTonix Pharma (TNXP) Says in General Its Proposed CMC Data Package to Support Tonmya's NDA and Commercial ... - StreetInsider.com
www.streetinsider.com - October 18 at 9:40 AM
Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSDTonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
finance.yahoo.com - October 17 at 8:11 AM

SEC Filings

Tonix Pharmaceuticals (NASDAQ:TNXP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Tonix Pharmaceuticals (NASDAQ:TNXP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tonix Pharmaceuticals (NASDAQ TNXP) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.